The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-study

Gabor Liposits; Stine B Winther; Jesper Ryg; Halla Skuladottir; Sören Möller; Eva Hofsli; Carl-Henrik Shah; Laurids Østergaard Poulsen; Åke Berglund; Camilla Qvortrup; Pia Osterlund; Bengt Glimelius; Halfdan Sorbye; Per Pfeiffer

doi:10.1016/j.jgo.2023.101632

The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-study

J Geriatr Oncol. 2024 Mar;15(2):101632. doi: 10.1016/j.jgo.2023.101632. Epub 2023 Sep 18.

Authors

Affiliations

¹ Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark. Electronic address: gabor.istvan.liposits@rsyd.dk.
² Department of Oncology, Odense University Hospital, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark.
³ Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark; Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark.
⁴ Department of Oncology, Regional Hospital Gødstrup, Herning, Denmark.
⁵ Department of Clinical Research, University of Southern Denmark, Odense, Denmark; OPEN - Open Patient data Explorative Network, Odense University Hospital, Odense, Denmark.
⁶ Department of Oncology, Trondheim University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
⁷ Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
⁸ Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
⁹ Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
¹⁰ Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark.
¹¹ Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland; Department of Oncology, Helsinki University Hospital, Helsinki, Finland; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
¹² Department of Oncology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway.
¹³ Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark.

PMID: 37730481
DOI: 10.1016/j.jgo.2023.101632

No abstract available

Keywords: BRAF(V600E); Chemotherapy; Colorectal cancer; Frailty; Older adults; Survival.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Colonic Neoplasms*
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Humans
Mutation
Proto-Oncogene Proteins B-raf / genetics
Rectal Neoplasms*
Treatment Outcome

Substances

Proto-Oncogene Proteins B-raf
BRAF protein, human